Hydroxyl Radical Damaged Thymidine-5’-Monophophate Presents Unique Epitopes for Cancer Antibodies

Rizwan Ahmad, Zafar Rasheed* and Rashid Ali

**Department of Biochemistry, Faculty of Medicine, J.N. Medical College, A.M.U. Aligarh-202002, India**

Abstract: Reactive oxygen species (ROS) plays an important role in carcinogenesis and hydroxyl radical (OH) contributes to the structural changes in DNA that characterize the cancer like phenotype. The role of hydroxyl radical (OH) damaged thymidine 5’-monophosphate (TMP) in cancer patients has been investigated in the present study. TMP was conjugated to bovine serum albumin (BSA), and then TMP-BSA conjugate was modified by hydroxyl radicals. Cancer patients (n = 99) were screened by direct binding ELISA for the detection of antibodies against native and ROS-modified conjugates and the results were compared with healthy age-matched controls (n = 29). High degree of specific binding by cancer serum antibodies towards ROS modified TMP-BSA conjugate, in comparison to unmodified conjugate, was observed. Healthy individuals showed negligible binding with either antigen. Competitive inhibition ELISA reiterates the direct binding results. Protein-A affinity purified IgG from cancer patients further substantiated the enhanced recognition towards modified conjugate as compared to unmodified conjugate. The present study clearly shows the perturbation in TMP-BSA conjugate by hydroxyl radical presenting unique neo-epitopes on TMP that might from one of the factors in antigen driven induction of antibodies in cancer patients.

INTRODUCTION

Cellular metabolism and ionizing radiation lead to the production of highly reactive oxygen species (ROS) in cells, like the superoxide anion radical, the hydroxyl radical and peoxynitrite etc. These species and their secondary intermediates react with cellular macromolecules and induce in them a variety of chemical alterations leading to carcinogenesis [1-3]. ROS may be looked as a causative agent at all stages of cancer namely initiation, promotion and progression [4]. Damage to DNA by ROS has been widely accepted as a major cause of cancer [5]. Human studies support the experimentally based notion of oxidative DNA damage as an important mutagenic and apparently carcinogenic factor [6]. DNA is considered to be most important target of oxygen free radical (OFR) attack [7]. Oxidative insult to DNA includes a range of specifically oxidized purine and pyrimidine bases as well as alcali labile sites and strand breaks [8,9]. If it relates to critical genes such as oncogenes or tumor suppressor genes, initiation/progression can result [10]. Immunological studies suspect a positive role for ROS-modified DNA in the etiology of cancer [11,12].

In our earlier study, we have shown that thymidine monophosphatate (TMP) linked bovine serum albumin (TMP-BSA) conjugate and its oxidized form was found to be immunogenic in experimental animals. Induced antibodies against TMP-BSA and ROS-modified TMP-BSA (ROS-TMP-BSA) conjugates exhibited appreciable cross-reactivity with various polynucleotides and nucleic acids [13]. In the present study, we have shown the cross reactivity of experimentally induced anti-TMP-BSA antibodies and anti-ROS-TMP-BSA antibodies against native and ROS-modified TMP-BSA conjugates with TMP alone, BSA alone and their ROS-modified conformers. The induced antibodies showed significant inhibition with TMP and ROS-TMP, respectively but with BSA and ROS-modified BSA these antibodies showed negligible inhibition. This suggested that anti-TMP-BSA antibodies and anti-ROS-TMP-BSA antibodies were mainly generated against TMP and ROS-TMP, respectively and BSA acts only as a carrier protein. In view of these, the present study was hypothesized that oxidative by-product, like hydroxyl radical (·OH) damaged TMP of DNA, help to initiate autoimmunity in cancer patients. We studied, the presence of circulating autoantibodies in various cancer patients sera directed against neo-epitopes which was generated by hydroxyl radicals on TMP of TMP-BSA.

MATERIALS AND METHODOLOGY

Collection of Sera

Sera (non-fasting) were collected from cancer patients with proven histo-pathological diagnosis from J.N. Medical College Hospital, A.M.U. Aligarh and from All India Institute of Medical Sciences, New Delhi. All cancer patients having disease for more than eighteen months and they continuing attending their Out Patient Departments (OPD), severity of cancer vary from patient to patients. The informed consent was obtained from each patient or from patients family members. Sera from normal, healthy individuals served as negative controls. All sera were decomplemented at 56°C for 30 minutes and stored in aliquots at -80°C.

Modification of Thymidine 5’-Monophosphate

TMP was modified in PBS (10 mM sodium phosphate buffer containing 150 mM NaCl, pH 7.4) by our published
ROS-TMP in Cancer

Preparation of Antigen

The TMP was covalently linked to BSA by the carbodiimide method [14]. Aqueous solutions of BSA (19 mg) and TMP (50 mg) were mixed and pH adjusted to 7.5 using NaOH, followed by the addition of 20 mg of carbodiimide, in a total volume of 5 ml. The reaction mixture was incubated in darkness at room temperature for 24 h. After incubation, the sample was dialyzed extensively against PBS (pH 7.4).

ROS-Modification of TMP-BSA Conjugate

TMP-BSA conjugate was modified in PBS (10 mM sodium phosphate buffer containing 150 mM NaCl, pH 7.4) by our published procedure [13,16]. An aqueous solution of TMP-BSA (6.2 mM) was modified by hydroxyl radical, generated by the UV-irradiation (30 min) of hydrogen peroxide (62 mM) at 254 nm. Excess hydrogen peroxide was removed by extensive dialysis against PBS (pH 7.4).

Purification of IgG

Immunoglobulin G (IgG) was isolated from cancer sera and healthy human sera using Protein A-Sepharose CL-4B column (Sigma Chemical, St. Louis, MO) [17,18]. The homogeneity of the isolated IgG was checked by performing 7.5% polyacrylamide gel electrophoresis.

Enzyme Linked Immunosorbent Assay

An ELISA was carried out on maxisorp immunoplates (NUNC, Roskilde, Denmark) as previously described [18]. Maxisorp microtitre immunoplates were coated with 100 μL modified or unmodified TMP-BSA conjugate (10 μg/mL) as antigens in carbonate bicarbonate buffer (0.05 mol/L, pH 9.6). The plates were coated for 2 h at 37°C and overnight at 4°C. Each sample was coated in triplicate and half of the plates served as controls without antigen coating. Unbound antigen was washed (3x) with TBS-T (20 mmol/L Tris, 150 mmol/L NaCl [pH 7.4] containing 0.05% Tween-20) and unoccupied sites were blocked with 2% fat-free milk in TBS (10 mmol/L Tris, 150 mmol/L NaCl [pH 7.4]) for 4–6 h at 37°C. After incubation the plates were washed (4x) with TBS-T. The test serum serially diluted in TBS-T (100 μL/well) or Protein-A purified cancer patients IgG in TBS (100 μL/well) was adsorbed for 2 h at 37°C and overnight at 4°C. Bound antibodies were assayed with anti-human alkaline phosphatase conjugate (Sigma Chemical, St. Louis, MO) using p-nitrophenyl phosphate as substrate (Sigma). The absorbance (A) of each well was monitored at 410 nm on an automatic microplate reader. Each sample was run in triplicate. The control wells were treated similarly. The results were expressed as mean of difference of absorbance values in test and control wells.

Competitive Inhibition ELISA

Antigenic specificity of the antibodies was determined by competition ELISA [15-18]. Varying amounts of inhibitors (0–20 μg/mL) were mixed with a constant amount of test serum (1:100 diluted) or affinity purified IgG. The mixture was incubated at room temperature for 2 h and overnight at 4°C. The immune complex formed was coated in the wells instead of IgG. The remaining steps were as for the direct binding ELISA. Inhibitors used were unmodified or modified TMP-BSA conjugate. Percentage inhibition was calculated using the formula: Percent inhibition was calculated using the formula:

\[ \text{Percent inhibition} = \frac{1 - (A_{\text{inhibited}} / A_{\text{uninhibited}})}{1} \times 100 \]

Statistical Analysis

Data are presented as mean ± SD. Significance of differences from control values were determined with the Student’s t test (Statgraphics, Origin 6.1). A value of \( p < 0.05 \) was considered to indicate statistical significance.

RESULTS

Characterization of ROS-Modified TMP

The UV absorption spectra of hydroxyl radical modified TMP indicated a complete loss of characteristic absorption at 260 (\( \lambda_{\text{max}} \)) after 30 min of irradiation (Fig. 1). A generalized spectrum getting stronger towards shorter wavelength was observed. No appreciable change in TMP absorption spectra was noticed when irradiated for 30 min in the absence of hydrogen peroxide.

Conjugation of TMP to BSA

The UV absorption of TMP-BSA conjugate showed a slight bathochromic shift when compared with TMP alone. The formation of TMP-BSA conjugate was ascertained on 7.5% non-reducing PAGE. The banding pattern indicated the formation of high molecular weight species as a consequence of conjugation. UV analysis of TMP-BSA conjugate gave a sharp peak at \( \lambda_{\text{max}} \) (269 nm), whereas ROS-modified conjugate indicated substantial hypochromicity and almost a complete disappearance of UV absorption maximum [13].

Cross Reactions of Anti-TMP-BSA Antibodies and Anti-Ros-TMP-BSA Antibodies

Immunoaffinity of TMP-BSA conjugate and ROS-modified TMP-BSA conjugate in rabbits induced high titre antibodies. Fifty percent inhibition of antibody binding was observed at an inhibitor concentration (IC\(_{50}\)) of 2.5 μg/ml and 3.5 μg/ml with TMP-BSA conjugate and ROS-TMP-BSA conjugate, respectively [13]. Here, we have shown the cross-reaction of experimentally induced anti-TMP-BSA antibodies and anti-Ros-TMP-BSA antibodies by competitive inhibition assay using TMP alone, BSA alone and their ROS-modified conformers as inhibitors. Competition ELISA with anti-TMP-BSA conjugate IgG showed the induced antibodies recognized TMP alone as it showed a maximum inhibition of 69%. ROS-TMP alone, BSA alone and ROS-BSA alone showed 28%, 10% and 11% inhibition, respectively. Table 1 (a) summaries the data of the binding characteristics of anti-TMP-BSA conjugate IgG. Competition ELISA with anti-Ros-TMP-BSA conjugate IgG showed a maximum inhibition of 86% with the ROS-TMP as inhibitor. TMP alone, BSA alone and ROS-BSA alone showed 39%, 11% and 13% inhibition, respectively. Table 1 (b) summa-
The study comprised of ninety nine sera from patients suffering from cancer of different organ and organ systems. Detection of Anti-ROS-TMP-BSA Antibodies in Cancer Sera

The average absorbance at 410 nm (±SD) of 99 different cancer sera binding to TMP-BSA and ROS-damaged TMP-BSA conjugate was 0.43 ± 0.12 and 0.79 ± 0.14, respectively. Whereas, the absorbance at 410 nm (±SD) of 29 healthy hu-

Table 1.

(a) Competitive Inhibition Data of anti-TMP-BSA IgG with Different Inhibitors

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Max. Percent Inhibition at 20 µg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMP alone</td>
<td>69 ± 4.7</td>
</tr>
<tr>
<td>ROS-TMP alone</td>
<td>28 ± 5.2</td>
</tr>
<tr>
<td>BSA alone</td>
<td>10 ± 2.6</td>
</tr>
<tr>
<td>ROS-BSA alone</td>
<td>11 ± 2.1</td>
</tr>
</tbody>
</table>

(b) Competitive Inhibition Data of anti-ROS-TMP-BSA IgG with Different Inhibitors

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Max. Percent Inhibition at 20 µg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMP alone</td>
<td>39 ± 1.1</td>
</tr>
<tr>
<td>ROS-TMP alone</td>
<td>86 ± 6.2</td>
</tr>
<tr>
<td>BSA alone</td>
<td>11 ± 1.2</td>
</tr>
<tr>
<td>ROS-BSA alone</td>
<td>13 ± 2.2</td>
</tr>
</tbody>
</table>

Each value represents mean ± S.D. of eleven independent assays.
The binding specificity of antibodies from the sera of cancer patients was evaluated by competition ELISA using TMP-BSA and ROS-modified TMP-BSA conjugate as inhibitors. Microtitre plates were coated with ROS-modified TMP-BSA conjugate. The average maximum percent inhibition (±SD) in the binding of 99 cancer sera to TMP-BSA and ROS-modified TMP-BSA conjugate was 29.3 ± 6.5 and 53.2 ± 11.8, respectively. The data reveals striking differences in the recognition of TMP-BSA conjugate and ROS-modified TMP-BSA conjugate by cancer antibodies (p<0.05). Table 2 summaries direct binding and competition ELISA results of each studied cancer population sera. Results points to a strong reactivity of cancer sera towards modified TMP-BSA conjugate over unmodified TMP-BSA conjugate.

IgGs were isolated from most of the cancer sera and also from healthy human sera using Protein-A sepharose CL-4B affinity column. The purified IgG was found to elute as a single symmetrical peak and gave a single band on SDS-PAGE (data not shown). Affinity purified cancer anti-TMP-BSA or anti-TMP-BM conjugates were calculated and compared with the titre of IgG from healthy human subjects. Majority of cancer IgG showed high titre to ROS-TMP-BM conjugate (p<0.001) (Fig. 3a), whereas same purified cancer IgG showed low titre with TMP-BSA conjugate (p>0.05) (Fig. 3b). The binding specificity of IgGs was investigated by inhibition ELISA using TMP-BSA and ROS-TMP-BSA conjugates as inhibitors. The microtitre plates were coated with ROS-TMP-BSA conjugate. Fig. (3c and d) illustrate inhibition of affinity purified cancer IgGs (three IgGs from breast and three IgGs from gall bladder cancer) binding to ROS-TMP-BSA and TMP-BSA conjugates. Results point to a higher reactivity of cancer IgGs towards ROS-damaged TMP-BSA conjugate over TMP-BSA conjugate (p<0.001) at 20 µg/ml of their respective inhibitor concentration. Similarly, the rest of the IgGs from other cancer population showed high percent inhibition with modified TMP-BSA conjugate.
Table 2. Immunological Details of Study Subjects

<table>
<thead>
<tr>
<th>Type of Cancer Patients</th>
<th>N</th>
<th>Age (Years) Mean ± SD</th>
<th>Detection of Anti-ROS-TMP-BSA Antibodies</th>
<th>Detection of Anti-TMP-BSA Antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>A₄₁₀</td>
<td>MPI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(ROS-TMP-BSA)</td>
<td>(TMP-BSA)</td>
</tr>
<tr>
<td>Breast</td>
<td>23</td>
<td>45.2 ± 7.2</td>
<td>0.84 ± 0.1</td>
<td>59.7 ± 13.1</td>
</tr>
<tr>
<td>Gall bladder</td>
<td>21</td>
<td>51.4 ± 6.4</td>
<td>0.77 ± 0.2</td>
<td>56.9 ± 15.7</td>
</tr>
<tr>
<td>Hepatocellular</td>
<td>22</td>
<td>58.3 ± 6.4</td>
<td>0.73 ± 0.2</td>
<td>43.8 ± 6.8</td>
</tr>
<tr>
<td>Lung</td>
<td>17</td>
<td>64.3 ± 4.1</td>
<td>0.78 ± 0.1</td>
<td>51.0 ± 10.9</td>
</tr>
<tr>
<td>Larynx</td>
<td>16</td>
<td>44.5 ± 10.6</td>
<td>0.82 ± 0.1</td>
<td>54.6 ± 12.7</td>
</tr>
<tr>
<td>HHS</td>
<td>29</td>
<td>55.8 ± 9.4</td>
<td>0.27 ± 0.2</td>
<td>17.7 ± 1.4</td>
</tr>
</tbody>
</table>

Na: Number of cancer tested sera; HHS: healthy human sera; A₄₁₀: absorbance at 410 nm calculated by direct binding ELISA; MPI: maximum percent inhibition at 20 µg/ml of inhibitor concentration calculated by competitive inhibition ELISA. *p < 0.05 vs. A₄₁₀(TMP-BSA); †p < 0.01 vs. MPI (TMP-BSA).

DISCUSSION

Malignant diseases are associated with the induction of autoimmunity that is characterized by the generation of autoantibodies against a wide array of autoantigens. Autoantibody activity has been identified in the sera of patients with solid tumors and in the sera of patients with hematological malignancies. The anti-tumor immune response may result in elicitation of autoantibodies against various autoantigens, including self antigens expressed in tumor cells - a large

Fig. (3). (a) Percentage of affinity purified cancer anti-ROS-TMP-BSA IgG (anti-RTB-IgG) titre compared with healthy human sera IgG (HH-IgG). (b) Percentage of affinity purified cancer anti-TMP-BSA IgG (anti-TB-IgG) titre compared with HH-IgG. Standard deviation has been indicated by a bar. The number of IgGs samples were 23 (breast), 21 (gall bladder), 22 (hepatocellular), 17 (lung), 16 (larynx) and 29 (healthy human). Inhibition ELISA of affinity purified IgG from breast (c) and gall bladder (d) cancer patients. The inhibitors used were TMP-BSA (○, △, ●) and ROS-TMP-BSA conjugate (■, ▲, ♦). The microtiter plates were coated with ROS-TMP-BSA conjugate (10 µg/ml).
Reactive oxygen species (ROS) generated during numerous metabolic and biochemical reactions have multifarious effects that include oxidative damage to DNA leading to various human degenerative diseases [2,3,12,20]. Cancer and aging are two biological consequences with the most complex etiology, and free radical-induced damage to DNA has been postulated to play a major role in their pathogenesis [10]. Native DNA is known to be a poor immunogen [21], whereas RNA-DNA hybrid, synthetic ribohomopolymers of poly (I), poly (U), poly (G) and calf-thymus DNA modified with drug, free radical, etc., have been reported to induce antibodies [22-24]. Despite of enzymatic repair and other defenses, continuous ROS damage and division of cells with unrepaired or misrepaired lesions lead to mutations. If these relate to critical genes such as oncogenes or tumor suppressor genes, initiation and/or progression of cancer can occur. Of the DNA bases thymine and guanosine are highly susceptible to hydroxyl radical modification to form products such as thymine glycol (Tg) and 5-hydroxymethyluracil (5-HMU) and 8-hydroxydeoxyguanosine (8-HDG). The Tg and 5-HMU have been detected in human urine in addition to 8-HDG thereby indicating their in vivo formation as a consequence of hydroxyl radical damage to DNA [25]. Studies have shown that 8-HDG is the major mutagenic lesion associated with increased risk of cancer. In our previous report, TMP and TMP-BSA were modified by hydroxyl radical, generated by UV-irradiation of hydrogen peroxide at 254 nm. Hydroxyl radicals caused extensive damage on TMP as evident by UV spectral studies. The observed hypochromicity was due to the structural alteration in TMP [13]. The antigens TMP-BSA, and ROS-TMP-BSA conjugates induced highly specific antibodies against their respective immunogens. Induced antibodies exhibited appreciable cross-reactivity with various polynucleotides and nucleic acid [13]. It is well documented that experimentally-induced antibodies to purines/pyrimidines conjugated to BSA are quite specific, but do cross-react with nucleic acids from various sources [26]. The diverse antigen-binding characteristics of the induced antibodies with a variety of polynucleotides and their ROS-modified forms might be due to the recognition of either the phosphodiester backbone or neo-epitopes on the molecules but the chances of neo-epitopes recognition by induced antibodies appears to be dominating in view of the practical negligible recognition of unmodified nucleic acids and their derivatives by induced antibodies [13,26]. In the present study, we demonstrated the cross reactivity of induced anti-TMP-BSA antibodies and anti-ROS-TMP-BSA antibodies to TMP and BSA alone and their ROS-modified conformers to find out which is the actual antigen for these antibodies. The anti-TMP-BSA antibodies and anti-ROS-TMP-BSA antibodies showed negligible inhibition with native and ROS-modified BSA alone, but these antibodies showed significant inhibition with both TMP alone and its ROS-modified form. This indicates that the induced anti-TMP-BSA antibodies and anti-ROS-TMP-BSA antibodies are mainly generated against TMP and ROS-TMP respectively, not against native BSA or ROS-modified BSA.

We know increased levels of circulating antibodies and autoantibodies have been reported in the serum of patients with malignancies directed against nucleus [25] and elevated levels of anti-nuclear antibodies (ANA) have been reported in the serum of cancer patients [27,28]. In view of these, present study was designed to evaluate the binding of circulating antibodies in cancer patients with TMP and ROS-modified TMP. In our study, sera from different types of cancer patients were screened for the presence of antibodies reactive to TMP-BSA and ROS-TMP-BSA conjugates. The study consists of 99 sera from patients of breast, gall bladder, hepatocellular, lung and larynx carcinomas having differences in the stage or other diagnostic parameters within each cancer type but all cancer patients were proven histopathological diagnosis and all cancer patients having disease for more than eighteen months and they continuing attending their O.P.D. at J.N. Medical College Hospital, A.M.U. Aligarh and All India Institute of Medical Sciences, New Delhi. Severity of cancer vary from patient to patients. The Majority of patients sera showed significantly higher recognition of ROS-modified TMP-BSA conjugate as compared to native TMP-BSA conjugate (p<0.05), whereas the antibodies present in the healthy human sera showed negligible binding to either of the conjugates (p>0.05). The binding of TMP-BSA and ROS-TMP-BSA conjugates with circulating cancer antibodies was further substantiated by Protein-A affinity purified cancer IgG by competition ELISA. Studies on the binding specificity of cancer antibodies clearly demonstrate that ROS-modified TMP-BSA conjugate is a better inhibitor
of naturally occurring antibodies in most of the cancer sera (or cancer IgG) investigated. The present study clearly shows the perturbations in TMP-BSA conjugate by hydroxyl radical presenting unique neo-epitopes on TMP that might form one of the factors in antigen-driven induction of antibodies in cancer patients.

The link between autoimmunity and cancer may result from a common aetiological origin (genetic, hormonal, or environmental factors) or, alternatively, from paraneoplastic syndromes. A large number of autoantibodies have been identified [2,3], these autoantibodies represent potentially valuable tools for identifying novel biomarkers and therapeutic targets. Recently, it has been proved that the inherent amplification of signals provided by the host’s own immune system to low levels of tumor-associated antigens in early disease provides a potential route to the early diagnosis of cancer [28,29]. Further studies are required to assess the diagnostic and/or prognostic value of autoantibodies reacting with polynucleotides, modified DNA, DNA-protein adducts, oncoproteins, tumor suppression genes, and/or proliferation associated antigens. The great studies in autoantibody testing over the last 20 years make it feasible to use specific autoantibody markers to improve diagnostic accuracy in systemic autoimmune disease. Circulating autoantibodies to self-antigens over expressed by cancer cells are common in cancer patients.

Our results demonstrate the presence of ROS-induced TMP damage in cancer patients, which might play an active part in the progression of disease mediated by mutations and subsequent neoplastic transformation of cells. Earlier studies report the use of antibodies to specific DNA base alterations, DNA-carcinogen adducts or to UV-DNA [30,31]. Some of these did not detect their target epitopes in macromolecular DNA. In contrast, the anti-ROS-TMP antibodies have been clearly shown to represent an alternative immunochemical probe to detect oxidative lesions in DNA from cancer patients, which could perhaps have a prognostic significance. These novel detection of oxidative thymidine-5’-monophosphate in cancer patients provide suggestions that the use of antioxidant or compounds that contain antioxidant may help human health.

COMPETING INTERESTS

The authors declare that they have no competing interests.

AUTHORS’ CONTRIBUTIONS

R. Ahmad carried out the experimental work. Z. Rasheed conceived of the study, coordination, data interpretation and drafting the manuscript. Study was designed by R. Ali.

ACKNOWLEDGEMENTS

The authors would like to thank Prof. Ashok Kumar for providing most of the cancer serum samples. Supported by a research grant from ICMR is gratefully acknowledged.

REFERENCES


